Disease Overview：Multiple Myeloma（MM）
Multiple Myeloma (MM) is a malignant plasma cell disorder characterized by clonal proliferation of abnormal plasma cells in the bone marrow, leading to end-organ damage—including hypercalcemia, renal insufficiency, anemia, and bone lesions (CRAB criteria). It accounts for approximately 10% of all hematologic malignancies and predominantly affects older adults, with median age at diagnosis around 69 years. Disease progression involves complex interactions between myeloma cells and the bone marrow microenvironment, driving immunosuppression, osteolytic destruction, and treatment resistance. Standard management includes risk-stratified induction therapy (e.g., proteasome inhibitor–immunomodulatory drug–dexamethasone regimens), autologous stem cell transplantation (ASCT) for eligible patients, maintenance therapy, and emerging options such as monoclonal antibodies (daratumumab, isatuximab), bispecific T-cell engagers (teclistamab), and chimeric antigen receptor (CAR) T-cell therapies targeting BCMA. Prognosis varies significantly by cytogenetic profile (e.g., del(17p), t(4;14)) and response depth, with median overall survival now exceeding 7–10 years in optimized settings.
China offers compelling advantages for MM care: nationally accredited hematology centers—such as Peking University People’s Hospital and Ruijin Hospital—host multidisciplinary myeloma programs led by ASH/EBMT-trained specialists with extensive experience in high-risk disease and novel immunotherapies. Advanced infrastructure includes next-generation sequencing for molecular profiling, flow cytometry-based minimal residual disease (MRD) assessment, and GMP-compliant CAR-T manufacturing facilities. Clinical outcomes align with international benchmarks: over 85% of transplant-eligible patients achieve ≥VGPR post-induction, and real-world MRD negativity rates exceed 60% after quadruplet regimens. Treatment costs remain substantially lower than in the US or Western Europe—ASCT with supportive care averages USD 35,000–45,000 versus USD 120,000+, while BCMA-targeted CAR-T therapy is priced at approximately USD 80,000 compared to USD 400,000+ abroad—without compromising quality or regulatory compliance. As a dedicated medical tourism agency, we facilitate seamless access to these resources: coordinating appointments with top-tier hematologists, verifying hospital accreditation and treatment protocols, providing itemized, transparent pricing in advance, and delivering end-to-end support—from visa assistance and medical translation to accommodation and post-treatment follow-up coordination.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Multiple Myeloma (Hematology Department)
Non-Surgical/Medical Therapy
*Target Criteria:* Newly diagnosed, relapsed/refractory, or maintenance candidates; requires confirmed monoclonal protein + clonal plasma cells ≥10% in bone marrow ± end-organ damage (CRAB criteria).
- •Induction Therapy (3–4 cycles)
- *Daratumumab + VRd (D-VRd):* ¥52,000–¥68,000/cycle ($7,200–$9,400)
- •Autologous Stem Cell Transplant (ASCT) Eligibility Workup
- Bone marrow biopsy + flow cytometry + FISH panel: ¥3,200 ($445)
- •Maintenance Therapy (post-ASCT or non-transplant)
- Daratumumab (subcutaneous, q8w): ¥18,600/dose ($2,580)
Surgical/Procedural/Interventional Options
*Eligibility:* Symptomatic lytic lesions with impending pathologic fracture, spinal cord compression, or refractory hypercalcemia unresponsive to medical therapy.
- •Vertebroplasty/Kyphoplasty (per level)
- Procedure + cement + fluoroscopy guidance: ¥14,200–¥19,800 ($1,970–$2,750)
- •Surgical Stabilization (e.g., spinal fusion)
- Open procedure (3–6 levels, instrumentation): ¥48,000–¥72,000 ($6,650–$10,000)
Special/Complex Condition Management
- •Renal Failure (Cast Nephropathy): High-cutoff hemodialysis + bortezomib + dexamethasone — ¥12,500/week ($1,730)
- •Plasma Cell Leukemia (PCL): Bortezomib + cyclophosphamide + dexamethasone + ASCT — total induction + transplant package: ¥185,000–¥240,000 ($25,600–$33,300)
- •Extramedullary Disease (EMD): Radiation (10 fractions, palliative): ¥8,900 ($1,235)
Quick Selection Guide
- •<65 years, fit, no major comorbidities: VRd induction → ASCT → lenalidomide maintenance (Total estimated: $32,000–$41,000)
- •65–75 years, moderate renal impairment: Daratumumab + lenalidomide + dexamethasone (DRd) without transplant ($28,000–$35,000 first year)
- •>75 years or frail (ECOG ≥2): Low-dose melphalan + prednisone + supportive care ($4,500–$7,200/year)
- •Budget-constrained (<$15,000): Bortezomib + dexamethasone monotherapy + bisphosphonates ($12,800–$14,500 first year)
- •Spinal cord compression: Urgent kyphoplasty + high-dose dexamethasone ($2,300–$3,100 immediate)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Multiple Myeloma Medical Vacation Packages
Curated transparent all-inclusive packages combining Multiple Myeloma treatment with China top medical destinations:
